No not yet, but page 3 sums it all up:
The Directors believe this trip has great significance for the Company. It will coincide with the
expected regulatory approval of Ropren – the first Russian developed pharmaceutical to be
registered in Russia for some 20 years. It will also showcase Ropren at a time when there is
an explosion in the incidence of liver disease – not just in Russia but throughout the world.
Cheers Greg